Barclays
KNSA icon

Barclays’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Barclays’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,000
Closed -$675K – 5382
2024
Q3 		$675K Buy
+27,000
New +$658K ﹤0.01% 3591
2024
Q2 		– Sell
-30,000
Closed -$592K – 5102
2024
Q1 		$592K Buy
30,000
+8,000
+36% +$156K ﹤0.01% 3481
2023
Q4 		$386K Buy
+22,000
New +$362K ﹤0.01% 4033

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Barclays's KNSA Position: Q1 2026 in Review

Barclays increased its Kiniksa Pharmaceuticals (KNSA) stake by 646% in Q1 2026, buying an estimated $1.31M and bringing the position to 34,152 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #2480.

Barclays first reported a position in KNSA in Q3 2018 and has held it in 31 quarters since. The position peaked at $12M in Q4 2020. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Barclays held 34,152 shares of Kiniksa Pharmaceuticals worth $1.64M as of Q1 2026.
  • Barclays bought 29,575 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $1.31M.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2480 holding.
  • Barclays first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • Barclays's Kiniksa Pharmaceuticals position peaked at $12M in Q4 2020.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.